There is a scarcity of studies evaluating statin discontinuation in patients with coronary artery
disease in real-world practice. In 11,144 patients who underwent first coronary …

In the much older population (≥ 80 years), the management of cardiovascular diseases
requires specific research to avoid a plain transposition of medical practice from younger …

Background Evidence-based medicine (EBM) has no doubt resulted in great improvements
in the practice of medicine. However, there are problems with overly zealous application of …

Atorva-, Simva-und Lovastatin werden primär über das Cytochrom-P450-System 3A4 der
Leber metabolisiert. Inhibitoren des CYP3A4-Systems erhöhen die Spiegel und damit das …

Background Current guidelines recommend that patients with established atherosclerotic
cardiovascular disease (ASCVD) use high-intensity statin therapy to lower low-density …

Aims Low-density lipoprotein cholesterol (LDL-C) reduction in hypercholesterolemia
patients at very high cardiovascular (CV) risk is essential in preventing future CV events. The …

The value of primary preventative therapies for cardiovascular disease (CVD) in older adults
(age≥ 75 years) is less certain than in younger patients. There is a lack of quality evidence …

Background/Objectives Older adults (> 75 years of age) represent two‐thirds of
atherosclerotic cardiovascular disease (ASCVD) deaths. The 2013 and 2018 American multi …

Do statins reduce mortality in older people? Findings from a longitudinal study using
primary care records - PMC Back to Top Skip to main content NIH NLM Logo Access keys …

Traditionally, data have been reported for the entire patient population of a given study,
registry or trial. If subgroups have been further investigated, they typically involved …